Ligand Pharmaceuticals Incorporated

LGND

US53220K5048

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-17 pm EDT			5-day change	1st Jan Change
80.64 ^USD	+0.72%		+1.40%	+12.91%

May. 13	Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing	MT
May. 08	Sector Update: Health Care Stocks Softer Late Afternoon	MT

Ligand Pharmaceuticals Incorporated Announces the Resignation of John Higgins as Director, Effective December 31, 2022

December 05, 2022 at 07:00 am EST

Ligand Pharmaceuticals Incorporated announced that John Higgins will resign as a director of the company on December 31, 2022.

Latest news about Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Insider Sold Shares Worth $830,449, According to a Recent SEC Filing	May. 13	MT
Sector Update: Health Care Stocks Softer Late Afternoon	May. 08	MT
Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views	May. 08	MT
Transcript : Ligand Pharmaceuticals Incorporated, Q1 2024 Earnings Call, May 07, 2024	May. 07
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M	May. 07	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q1 EPS $1.20, vs. Street Est of $0.83	May. 07	MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024	May. 07	CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	May. 07	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	May. 07	MT
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	Apr. 08	CI
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer	Apr. 03	CI
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics	Apr. 02	CI
Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance	Feb. 27	MT
Transcript : Ligand Pharmaceuticals Incorporated, Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024	Feb. 27	CI
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 Revenue $28.1M, vs. Street Est of $25.7M	Feb. 27	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 EPS $1.05, vs. Street Est of $0.66	Feb. 27	MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 27	CI
Ligand Pharmaceuticals Incorporated Announces Management Appointments	Feb. 16	CI
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	Jan. 08
Investors lower their expectations	Jan. 08
Ligand Pharmaceuticals Secures FDA Approval for Viral Skin Infection Medication; Shares Jump Premarket	Jan. 08	MT
Ligand Pharmaceuticals Gets FDA OK for Viral Skin Infection Treatment	Jan. 05	DJ
Ligand Pharma's at-home skin treatment gets FDA approval	Jan. 05	RE

Chart Ligand Pharmaceuticals Incorporated

Duration

Period

Chart Ligand Pharmaceuticals Incorporated

More charts

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.

Sector

Pharmaceuticals

Calendar

2024-08-04 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Ligand Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

80.64 USD

Average target price

116.8 USD

Spread / Average Target

+44.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIGAND PHARMACEUTICALS INCORPORATED	+12.91%	1.44B
ELI LILLY AND COMPANY	+51.82%	791B
NOVO NORDISK A/S	+40.45%	630B
MERCK & CO., INC.	+16.95%	328B
ABBVIE INC.	+9.49%	298B
ASTRAZENECA PLC	+17.25%	246B
ROCHE HOLDING AG	+0.41%	225B
NOVARTIS AG	+10.22%	218B
AMGEN INC.	+5.30%	160B
PFIZER, INC.	-6.29%	156B

Other Pharmaceuticals